27.45
-0.22(-0.80%)
Currency In USD
Address
512 2nd Street
San Francisco, CA 94107
United States of America
Phone
650 243 5555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
96
First IPO Date
November 19, 2020
| Name | Title | Pay | Year Born |
| Sean Bohen | President, Chief Executive Officer & Director | 1.12M | 1967 |
| David C. Myles | Chief Discovery & Non-Clinical Development Officer | 200,000 | 1963 |
| Naseem Zojwalla | Chief Medical Officer | 777,970 | 1973 |
| Shane William Charles Kovacs | Chief Operating & Financial Officer | 845,370 | 1974 |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | 0 | N/A |
| Mark Shilkrut | Senior Vice President of Clinical Development | 0 | N/A |
| Richard Hernandez | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Courtney O'Konek | Vice President of Corporate Communications | 0 | N/A |
| Julie Dexter | Senior VP & Head of People | 0 | N/A |
| Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | 0 | 1978 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.